NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rob-Chemist who wrote (326)	3/4/1999 10:46:00 PM
From: Miljenko Zuanic	Read Replies (1) of 328

Rob, Chris, and others: Many today (based on NXTR price move) quickly develop opinion that NXTR may do better as standalone company. Yes, NXTR may have lower risk than GILD, but also has significantly lower potential. AmBisome is what it is (maybe 150 M drug) and MiKasome (because of the management stupidity) will not reach market for at least next three years. So, near term small profitability is BS and fiction and if one think that flat price (range 8-14) for next two years is his objective, let it be. Sell now and kiss for good buy. I was GILD SH in 96/97 and part 98, and am glad that they merge with NXTR. Combined it is serious small pharma company. If future management can do job right we will be satisfied. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next